Protagenic Therapeutics Files 8-K: Material Agreement & Equity
Ticker: PTIXW · Form: 8-K · Filed: Oct 30, 2024 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | 8-K |
| Filed Date | Oct 30, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $0.64, $0.89, $1.275 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-securities, regulation-fd
Related Tickers: PTIX
TL;DR
PTIX filed an 8-K for a material agreement and unregistered equity sales - check the details!
AI Summary
On October 29, 2024, Protagenic Therapeutics, Inc. entered into a material definitive agreement, likely related to the issuance of unregistered equity securities. The company also made a Regulation FD disclosure and filed financial statements and exhibits.
Why It Matters
This filing indicates significant corporate activity, potentially involving new financing or strategic partnerships that could impact the company's future operations and stock value.
Risk Assessment
Risk Level: medium — Filings related to material definitive agreements and unregistered equity sales can introduce uncertainty and potential dilution, warranting careful review.
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — Filer of the 8-K report
- October 29, 2024 (date) — Date of the earliest event reported
- 0001493152-24-042964 (accession_number) — Unique identifier for the filing
FAQ
What is the nature of the material definitive agreement entered into by Protagenic Therapeutics?
The filing indicates an 'Entry into a Material Definitive Agreement' as an item information, but the specific details of the agreement are not provided in the provided text.
What type of unregistered securities were sold by Protagenic Therapeutics?
The filing lists 'Unregistered Sales of Equity Securities' as an item information, suggesting the sale of equity, but the specific type and amount are not detailed in the provided text.
What is the significance of the Regulation FD Disclosure mentioned in the filing?
A Regulation FD Disclosure is made to ensure that material non-public information is broadly disseminated to the public, preventing unfair advantages for certain investors.
When was this 8-K filing submitted to the SEC?
The filing was submitted on October 30, 2024, as indicated by the 'FILED AS OF DATE'.
What was Protagenic Therapeutics' former company name?
Protagenic Therapeutics, Inc. was formerly known as Atrinsic, Inc. (name change on 20090630), NEW MOTION, INC. (name change on 20070504), and MPLC, Inc. (name change on 20050608).
Filing Stats: 1,590 words · 6 min read · ~5 pages · Grade level 12.3 · Accepted 2024-10-29 21:52:19
Key Financial Figures
- $0.0001 — common stock (the "Shares"), par value $0.0001 per share ("Common Stock"), (or pre-fun
- $0.64 — rant Shares") with an exercise price of $0.64 per share (subject to adjustment as des
- $0.89 — ciated Common Stock Warrants was $0.64 ($0.89 in the case of insiders). The closing
- $1.275 m — rom the Transaction were approximately, $1.275 million, before deducting fees and other
Filing Documents
- form8-k.htm (8-K) — 62KB
- ex4-1.htm (EX-4.1) — 129KB
- ex4-2.htm (EX-4.2) — 121KB
- ex4-3.htm (EX-4.3) — 120KB
- ex10-1.htm (EX-10.1) — 273KB
- ex10-2.htm (EX-10.2) — 178KB
- ex99-1.htm (EX-99.1) — 10KB
- 0001493152-24-042964.txt ( ) — 1287KB
- ptix-20241029.xsd (EX-101.SCH) — 4KB
- ptix-20241029_def.xml (EX-101.DEF) — 29KB
- ptix-20241029_lab.xml (EX-101.LAB) — 36KB
- ptix-20241029_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROTAGENIC THERAPEUTICS, INC. Date: October 29, 2024 By: /s/ Alexander K. Arrow Name: Alexander K. Arrow Title: Chief Financial Officer 4